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ttp://dx.doi.org/10.1016/j.ajpath.2012.09.012HACE1 is an E3 ubiquitin ligase located in 6q21, the genomic region frequently deleted in natural killer
(NK) cell malignancies. Here, we report HACE1 as a candidate tumor suppressor gene silenced through
a combination of deletion and cytosine phosphate guanine island hypermethylation. We detected
deletion of HACE1 in malignant NK cell lines (6 of 9, 67%) and primary biopsies (5 of 15, 33%) by
quantitative PCR, with most of the specimen showing cytosine phosphate guanine island hyper-
methylation in the remaining allele, leading to low mRNA transcription. The ectopic expression of HACE1
in an HACE1-null NK cell line led to apoptosis and G2/M cell cycle arrest. Moreover, HACE1 expression
was up-regulated in IL-2-activated normal NK cells and NK cells cocultured with an engineered NK cell
target, K562 Clone 9.mbIL21, suggesting its role in the regulation of NK cell homeostasis. In conclusion,
HACE1 is another potent tumor suppressor gene located within the 6q21 region, and loss of function of
multiple tumor suppressor genes within 6q21 may be a critical determinant of NK cell lymphomagenesis.
(Am J Pathol 2013, 182: 49e55; http://dx.doi.org/10.1016/j.ajpath.2012.09.012)Supported by Lymphoma SPORE P50CA136411-01(NCI) (W.C.C. and
J.I.) and a grant from the National Cancer Institute (5U01/CA114778).
C.K. and X.H. contributed equally to this work.HACE1 belongs to the HECT family of ubiquitin ligases
(HECT E3), which have the unique capability of intrinsic
catalytic activity and speciﬁcity for substrates involved in the
regulation of growth and apoptosis such as p53, p73, and
phosphatase and tensin homologue.1 HECT E3s have been
shown to be involved in cancer development because of their
capability of targeting speciﬁc genes for proteosomal degra-
dation associated with cellular growth and survival.1
A comprehensive study reported HACE1 as a tumor
suppressor gene, which was involved in the spontaneous
tumorigenesis in several cancers in vivo.2 Knock-down of
HACE1via small-interferingRNAconverted nontumorigenic
cell lines to tumorigenic ones and HACE1 cooperated with
p53 in tumor suppression.2 HACE1 was shown to be silenced
in Wilms tumor cases,2,3 and HACE1 silencing was shown to
be mediated through hypermethylation of the two cytosine
phosphate guanine (CpG) islands, CpG-29 and CpG-177,
located upstream of the transcription start site (TSS).2 CpG-
177 hypermethylation of HACE1 was frequently observed
in colorectal and gastric carcinomas,4,5 and the association
of HACE1 hypermethylation with the clinicopathologicstigative Pathology.
.ﬁndings, especially lymph node metastasis, has been shown
for colorectal carcinomas.4HACE1was reported to be located
in the frequently deleted 6q21 locus by array comparative
genomic hybridization (aCGH), and HACE1 expression was
down-regulated in natural killer cell lymphoma/leukemia
(NKCL) samples.6,7 However, the role of CpG island meth-
ylation on HACE1 silencing was not evaluated in those two
studies, and the frequency of hemizygous deletion of HACE1
detected by the aCGH platforms (30% to 40% of the cases)
was not sufﬁcient enough to account for the down-regulation
of HACE1 in NKCLs.
HACE1 was shown to inhibit the tumor suppressor gene
RARb,8 to ubiquitylate Rac19da gene involved in cell
proliferation and G2/M cell cycle progression,
10 and to
regulate Golgi biogenesis during cell cycle.11 It was shown
to target and degrade cyclinD1 in HEK293T cells.2 Those
studies suggest that loss of function of HACE1 in NKCLs
Küçük et almay be associated with the deregulation of its target genes
associated with cell cycle and/or apoptosis in NK cells that
contribute to the neoplastic transformation of NK cells.
Here, we report the silencing of HACE1 in NK cell
malignancies through a combination of deletion and CpG
island hypermethylation and show the tumor suppressive
role of HACE1 in NK cell lines through functional assays.
Materials and Methods
Patient and Cell Line Material
The characteristics of NK cell tumor cases and NK cell lines
have been reported earlier12 and are summarized in
Supplemental Table S1. DNA and RNA were isolated with
AllPrep DNA/RNA mini kit (Qiagen Inc., Valencia, CA).
All NK cell lines were cultured in RPMI 1640 (Gibco-
Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf
serum, penicillin G (100 U/mL) and streptomycin (100 mg/
mL), and 5 to 7 ng/mL IL-2 (R&D Bioscience, San Diego,
CA) at 37C in 5% CO2.
HACE1 Copy Number Analysis
Copy number analysis of HACE1 was performed with
quantitative real-time PCR (qPCR) with the use of primers
designed against the HACE1 genomic DNA by applying the
same qPCR-based method used earlier for the detection of
monoallelic deletion of PRDM1 in diffuse large B-cell
lymphomas and NKCLs, respectively.12,13 Brieﬂy, the copy
number of HACE1 is normalized to a reference gene, and the
normalized copy number was compared with a control
sample [ie, freshly isolated human peripheral blood (PB) NK
cells] that was considered to have no genomic abnormality. If
the normalized numeric value of the sample was less than the
cutoff value (0.75-fold of the control sample), the sample was
considered to have the deletion. Genomic DNA (20 ng) was
used as the template for qPCR. RPL13A was used as the
reference gene to normalize the copy number.12 The HACE1
primers used for copy number analysis were as follows:
forward, 50-AACTCTTAGTTCCAGGGTCCCACA-30, and
reverse, 50-TTGGAGTATATGGCACAGCAGCGA-30.
FISH Analysis of NK Cell Lines
Standard interphase ﬂuorescent in situ hybridization FISH
study was performed on NK92 and KAI3 cell suspensions
with the use of direct-labeled centromere probes for chro-
mosome 6 (Abbott/Vysis, Inc., Abbott Park, IL) and the
HACE1 gene region (6q21; Empire Genomics, Buffalo, NY).
FISH was performed by co-denaturation on a ThermoBrite
instrument (Abbott-Vysis, Inc.) at a denaturation temperature
of 75C for 1 minute, followed by an overnight hybridization
at 37C. The slides were then washed with 0.4 standard
saline citrate/0.3% NP-40 at 72C for 2 minutes, followed by
a 1-minute wash in 2 standard saline citrate/0.1% NP-40 at50room temperature. The cells were counterstained with DAPI
II and viewed on a Leica DM5500B microscope (Leica,
Wetzlar, Germany) equipped with appropriate ﬁlters. One
hundred interphase nuclei were examined for each probe.
Quantiﬁcation of the HACE1 mRNA
HACE1mRNA expression was determined with quantitative
RT-PCR (RT-qPCR) in malignant NK cell lines, NKCL
cases, IL-2-activated peripheral blood NK cells, or human
peripheral blood NK cells activated by coculturing with an
engineered K562 cell line (K562 Clone 9.mbIL21) kindly
provided by Dr. Dean A. Lee (MD Anderson Cancer Center,
Houston, TX). The K562 Clone 9.mbIL21 cell line was
derived from the K562 cells, an erthyroleukemia cell line
originated from a patient with chronic malignant leukemia
with blast crisis,14 engineered to express additional activation
molecules (ie, 4-1BBL, CD86, and mbIL21) on the cell
surface so that robust signals of NK cell activation can be
obtained.15 The rationale of choosing the engineered K562
cell line was to address whether HACE1 expression is
up-regulated during NK cell activation, suggesting a possible
functional role for HACE1 during NK cell activation. NK
cells activated by K562 Clone 9.mbIL21 cells can be
expanded, allowing longer periods of observation time. In
addition, this model provided us with the opportunity to
observe HACE1 expression in the later stages of activation of
NK cells, which can be determined by the time period at
which the engineered K562 cells are cleared by the cytotoxic
action of NK cells. Melting curve analysis was performed
to ensure PCR-band speciﬁcity. DDCt method was used
for the RT-qPCR data analysis. RPL13A16 was used as
the housekeeping gene to calibrate HACE1 expression.
TheHACE1RT-qPCR primers used were as follows: forward,
50-CCAGTTATTCAGTGGTTCTGGGAAG-30, and reverse,
50-CCACCCATGATATTAGCAAACCCACC-30.
Methylation Analysis of HACE1
HACE1 promoter methylation was determined with the
methylation-speciﬁc cell counting (MSCC) procedure as
described earlier17 in NKCL cases (n Z 11) and with the
use of quantitative Methyl-speciﬁc PCR (qMSP) in NK cell
lines (n Z 7). We speciﬁcally concentrated on the CpG
islands close to the promoter of HACE1, whereas the
complete methylation proﬁle by MSCC will be published
separately. The library preparation and high-throughput
sequencing was performed at the epigenetic core labora-
tory facility by Illumina Genome Analyzer II X. To deter-
mine the signiﬁcance of change in count data, an analysis
for ﬁt that was based on the Poisson distribution at the
P Z 0.05 level was used. On the basis of this analysis,
a signiﬁcant change was determined to be a fourfold or
greater difference between two samples. qMSP has been
performed on seven NK cell lines with the use of previously
reported MSP primers2 with the EZ DNA Methylation-Goldajp.amjpathol.org - The American Journal of Pathology
HACE1 Is a Tumor Suppressor Gene in NKCLskit (Zymo Research, Orange, CA) and 250 ng of genomic
DNA as the template. DyNAmo HS SYBR Green qPCR kit
(Finnzymes, Waltham, MA) was used for qPCR. Resting
PB NK cells were used as the unmethylated control, M. SssI
(New England Biolabs, Ipswich, MA) methylated human
lymphocyte genomic DNA (Roche Diagnostic Corporation,
Indianapolis, IN) was used as the methylated control for
qMSP, and 48-hour IL-2-activated PB NK cells were used
as the control for MSCC. The differential methylation in
NKCL cases compared with the control was calculated
according to the count data. The primer sequences used for
qMSP are as follows: CpG-177 forward, 50-GAATGG-
AAGGTTTAATTTCGC-30, and CpG-177 reverse, 50-CT-
AAAACCCTACGTCAACCG-30.
Mutation Analysis of HACE1 in Malignant NKCL Cases
RNA-seq has been performed on eight NKCL cases. In this
study, we concentrated on HACE1, and the complete tran-
scriptomic proﬁle will be published later. The RNA-seq data of
the HACE1 coding sequence and intron/exon junctions were
analyzed with Integrative Genomics Viewer software version
2.0 (http://www.broadinstitute.org/igv) to screen for possible
mutations. If suspected for a splice sitemutation,DNAfrom the
corresponding NKCL case was PCR-ampliﬁed with primers
spanning theHACE1 intron/exon splice junctions. The primers
used in the mutation analysis are listed Table 1.
Reconstitution of HACE1 in Malignant NK Cell Lines
HACE1-pCMV6-XL4 (Origene, Rockville, MD) was used as
the HACE1 source sequence during cloning of expression
plasmids. The National Center for Biotechnology Information
reference sequenceused forHACE1 isNM_020771.2.HACE1
coding sequences were PCR-cloned with the high-ﬁdelity
PfuUltra II Fusion HS DNA Polymerase (Agilent Technolo-
gies, Palo Alto, CA) upstream of the internal ribosome entry
sitewith the use of theNotI and SalI sites into PMIG. Sequence
validation of all of the inserts was performed by Sanger
sequencing. HACE1 retroviral construct generated and used in
this study are shown (Supplemental Figure S1). The retroviral
transduction was performed as described previously.12
Apoptosis and Cell Cycle Assays
Apoptosis of retrovirally transduced cells was quantiﬁed
with a FACSCalibur ﬂow cytometer (BD Biosciences, San
Jose, CA) after staining the cells with Annexin V-PETable 1 HACE1 Mutation Analysis Primer Sets (NC_000006.11)
Location Forward
68169-68760 50-TGAAACAGATGGTCAGTGGGATGA-30
74341-75180 50-GGCATTACTATCACGTTAACTTGGGAAG
74401-74860 50-GGCATTACTATCACGTTAACTTGGGAAG
75541-76140 50-TCAGTGTCAGTGTATCTGAATTTGC-30
82381-82980 50-GGTAGTCAAACTATTTCAGCTAAGTTCT
The American Journal of Pathology - ajp.amjpathol.org(Apoptosis Detection Kit; BD Pharmingen, San Diego, CA)
according to the manufacturer’s instructions. The cell cycle
proﬁle of retrovirally transduced cells was analyzed with
Hoechst 33342 staining (H3570; Invitrogen, Carlsbad, CA).
The cells were washed once with phosphate-buffered saline
(PBS) and resuspended in buffer containing 1 PBS plus
0.1% bovine serum albumin at 0.5  106 cells/mL. Hoechst
dye was added to the cells at a ﬁnal concentration of
10 mg/mL. The cells were incubated at 37C for 15 minutes
and then analyzed with a BD LSR II ﬂow cytometer.
Isolation of Primary NK Cells from the Peripheral Blood
Normal NK cells were isolated from the peripheral blood of
healthy donors with negative selection with the use of the
NK Cell Isolation Kit (Miltenyi Biotech, Auburn, CA). The
purity of NK cells was determined with CD56-APC/CD3-
PE double staining and FACSCalibur ﬂow cytometry
(Supplemental Figure S2A).
NK Cell Activation by Coculturing Peripheral Blood
Lymphocytes with the Engineered K562 Cells
Derivationof primaryNKcells from the coculture of peripheral
blood lymphocytes and K562 Clone 9.mbIL21 was performed
as described earlier.15 Brieﬂy, 1.5  106 peripheral blood
lymphocytesweremixedwith 100-Gy irradiated 3 106K562
Clone 9.mbIL21 cells (1:2 ratio). Seven days after stimulation,
second stimulation was performed by combining cocultured
cells with fresh irradiated engineered K562 cells (1:1 ratio).
The proportion of NK cells in the cocultured population was
determinedwithﬂowcytometrywith the use ofCD56 andCD3
surface staining 7, 12, and 14 days after the coculture
(Supplemental Figure S2, B and D), and CD56þ/CD3 cells
were considered as human NK cells as described earlier.18
Statistical Analysis
Statistical analysis was performed with Student’s t-test.
P < 0.05 was considered signiﬁcant.
Results
Deletion and CpG Island Methylation Is Frequent and
Cooperates in Silencing of HACE1 in NKCL Cases
Previously, hemizygous deletion of HACE1 was observed
only inw37.5% of the NKCL cases.6 Consistent with theseReverse
50-AGCATGGTGGCTGCATATTACA-30
AT-30 50-ACAAGGTGACATTCACCATTCTACA-30
AT-30 50-ACATCCTGACAATCTGCACTGGCT-30
50-GCTCCTTTCAGGAAATGTGGCA-30
G-30 50-ATGCCTTCTTCTCCATGGAACCGT-30
51
Figure 1 HACE1 is silenced through a combination of hemizygous deletion and CpG island hypermethylation in NKCL samples. A and B: NK cell lines and NKCL
cases with or without deletion were determined by the HACE1/RPL13A ratio for each sample. NKCL cases with HACE1/RPL13A<0.75 that of human resting primary
PBNK cell DNAwere deﬁned to have deletion.HACE1/RPL13A for each sample represented the average of two independent experiments for bothHACE1 and RPL13A.
The deletion status of the NKCL cases by aCGHwas shownwith the signs at the bottomof the ﬁgure. The plus sign indicates a hemizygous deletion in theminimal
common region of 6q21 according to the two previous reports that applied bacterial artiﬁcial chromosome-aCGH on NK cell lines and NKCL cases16 or Cartes
d’Identité des Tumeurs CGH on NKCL cases.19 The dashed horizontal bar represents the cutoff used to determine the deletion status of the NK cell lines and NKCL
cases. C: Quantiﬁcation of HACE1mRNA in NK cell lines. The HACE1mRNA expression in NK cell lines was determined with RT-qPCR. Relative expression values were
normalized to the values of the resting NK cells. Resting and 4-day IL-2eactivated primary PB NK cells were used as control. Data are means  SDs of two
experiments.D: Hypermethylation of the three CpG islands, CpG-29, CpG-177, and CpG-88, in NKCL caseswas determinedwithMSCC. The differentialmethylation of
the HpaII sites was shown after normalization of the HpaII count sites to the count sites of the 48-hour IL-2eactivated peripheral blood NK cells. Gray (4- to 10-
fold) and black (>10-fold) boxes show the hypermethylatedHpaII sites. E: HACE1mRNAexpression in sevenNKCL cases. HACE1mRNAexpression in NKCL caseswas
normalized to the HACE1 expression in resting PB NK cells. Resting and 4-day IL-2eactivated PB NK cells were used as the controls. The HACE1 deletion status was
markedwithplus andminus signs on the x axis. F: The total number of hypermethylatedHpaII sites (ie, hypermethylated HpaII sites in CpG-177, CpG-88, and CpG-
29 altogether) (left panel) and the number of hypermethylatedHpaII sites in each CpG island comparedwith normal 48-hour IL-2eactivatedNK cells (right panel)
were indicated for the sameNKCL cases with the same sample order as in E. Fourfold countwas set as the threshold for hypermethylation.G: MSP-qPCR results of the
seven malignant NK cell lines are shown. Resting NK cells (NK0) were used as the negative, and M.SssI methylated lymphocyte DNA (Met) was used as the positive
control, respectively. DCt values are calculated as follows: (CtNK cell line  CtNK0).
Küçük et alobservations, we observed monoallelic deletion of HACE1 in
6 of 9 (67%) NK cell lines (Figure 1A) and 5 of 15 (33%)
NKCL cases (Figure 1B) with the use of the qPCR method
for monoallelic deletion reported recently.12,13 In general,
monoallelic deletion ofHACE1 detected by qPCR in NK cell
lines and NKCL cases (8 of 9, 89%, for the NK cell lines and
13 of 15, 87%, for the NKCL cases) were present in the
samples that have the monoallelic deletion of the 6q21
minimal common region locus detected in previous studies by
bacterial artiﬁcial chromosome aCGH16 or Cartes d’Identité52des Tumeurs aCGH.19 We evaluated HACE1 copy number
status with FISH on NK92 and KAI3 cell lines that have no
deletion or HACE1 deletion detected by qPCR, respectively.
Consistent with the ﬁndings with qPCR assay, we observed
monoallelic deletion of HACE1 in KAI3 but not in the NK92
cell line (Supplemental Figure S3). To address whether
monoallelic deletion ofHACE1 decreasedmRNAexpression,
we performed RT-qPCR on six NK cell lines and observed
lower HACE1 expression in four NK cell lines with deletion
(Figure 1C).ajp.amjpathol.org - The American Journal of Pathology
Figure 2 Reconstitution of HACE1 in a HACE1-null NK cell line induces apoptosis and cell cycle arrest. A: Vector or HACE1-transduced KAI3 cells were
stained with Annexin V-PE and tested with ﬂuorescence-activated cell sorting. B: Ectopic expression of HACE1 caused apoptosis in the KAI3 cell line (vector:
9.74%  0.92%, nZ 2; HACE1: 89.04%  0.21%, nZ 2). The rate of apoptosis was determined by measuring the proportion of Annexin Vþ cells in the GFPþ
population 2 days after transduction. Data are means  SDs of two independent experiments. *P < 0.001 versus vector. C: Vector- or HACE1-transduced KAI3
cells were stained with Hoechst 33342, and the cell cycle proﬁle on the GFP-gated population of vector- or HACE1-transduced KAI3 cells was determined with
ﬂuorescence-activated cell sorting. D: Ectopic HACE1 expression causes G2/M cell cycle arrest in the KAI3 cell line [(%HACE1  %Vector); (DG0/G1Z 23%,
DSZ 1%, DG2/MZ 12.9%)]. Data are means  SDs of two independent experiments. E: HACE1 mRNA expression was determined in IL-2eactivated PB NK
cells. RPL13A was used as the housekeeping gene for normalization. F: HACE1 mRNA expression in cocultured primary NK cells is shown. *P < 0.05 versus
Resting NK cells. G: Ectopic expression of HACE1 in KAI3 cells. RT-qPCR was applied on GFPþ KAI3 cells sorted 42 hours after transduction with vector or HACE1.
RPL13A was used as the housekeeping gene for normalization. Data are means  SDs of two independent experiments. *P < 0.001 versus vector.
HACE1 Is a Tumor Suppressor Gene in NKCLsNext, we evaluated the inﬂuence of the CpG island meth-
ylation on HACE1 expression as an epigenetic mechanism of
gene silencing. Three CpG islands were reported around or
upstream of the TSS for HACE1.3 The hypermethylation-
associated silencing of the upstream CpG islands, CpG-177
and CpG-29, was shown in Wilms tumor,2 and hyper-
methylation of CpG-177 was detected in a variety of solid
tumors.2e5 Consistent with the previous reports, we observed
hypermethylation of at least one HpaII (CCGG) site for the
CpG-177 (81715 to 80475 of TSS) in all NKCL cases
compared with the activated NK cells by MSCC (Figure 1D).
CpG-88, the CpG island around the HACE1 TSS, had hyper-
methylated sites; however, the frequency of hypermethylation
was lower than that observed for the CpG-177, and there was
one hypomethylated site (360 of TSS) in 9 of 11 (82%) NKCL
cases.We had oneMSCC site fromCpG-29, and 5 of 11 (45%)
of the NKCL cases had hypermethylation at this site. Next, we
determined HACE1 expression in seven NKCL cases by RT-
qPCR (Figure 1E). We observed lower HACE1 expression in
NKCLcases having higher numbers of hypermethylatedHpaIIThe American Journal of Pathology - ajp.amjpathol.orgsites in NKCL cases, and the cases with deletion and high
quantity of hypermethylated sites had the lowest mRNA
expression (Figure 1, E and F). The association between CpG
island hypermethylation and lowHACE1 expressionwasmore
obvious in CpG-177 than in CpG-88 and CpG-29 (Figure 1F).
We determined CpG-177 methylation in 6 of 7 (86%) NK cell
lines with MSP (Figure 1G).
Mutation Analysis of HACE1 in the Malignant NKCL
Cases
RNA-seq showed retention of introns 11 and 15 in two of
eight NKCL cases; however, no mutations were detected in
the coding region. Insufﬁcient splicing may lead to loss of
function of HACE1 that can cooperate with deletion and
CpG island methylation. The retention of the introns may be
due to insufﬁcient splicing that may be related to the
mutations in the intron/exon junctions. To evaluate whether
there was any mutation in the intron/exon junctions leading
to aberrant splicing, we designed primers targeting the53
Küçük et algenomic DNA that spanned these junctions. Sanger
sequencing of the intron/exon junctions spanning the exons
11 to 12 and 14 to 15 for the corresponding NKCL case did
not show any single nucleotide variations in the intron/exon
junctions screened.
Ectopic Expression of HACE1 in an NK Cell Line Leads
to Cell Cycle Arrest and Apoptosis
We tested the functional consequence(s) of the ectopic
expression of HACE1 in the KAI3 cell line, an NK cell line
with del6q21 and low HACE1 expression. We directly
tested cell cycle and apoptosis in green ﬂuorescent protein
(GFP)þ, unsorted cells with Hoechst and Annexin V
staining. We observed increase in apoptosis (Figure 2, A
and B) and induction of G2/M cell cycle arrest in KAI3 cells
transduced with HACE1 compared with the vector-only
control 2 days after transduction (Figure 2, C and D).
HACE1 Is Up-Regulated during Normal NK Cell
Activation
Next, we asked whether HACE1 expression was altered on
NK cell activation. To address this question, we tested
HACE1 expression in IL-2-activated human peripheral
blood NK cells and observed up to a fourfold increase in
a 6-day period (Figure 2E). We observed a similar
progressive up-regulation of HACE1 between days 13 and
18 in NK cells cocultured with engineered K562 cells,
which reached 10-fold compared with the levels in resting
NK cells, suggesting a possible role of HACE1 in the
regulation of NK cell activation and homeostasis
(Figure 2F). Ectopic expression of HACE1 has been shown
with RT-qPCR on transduced KAI3 cells (Figure 2G).
Discussion
Monoallelic deletion of the 6q21 locus (del6q21) is one of the
most recurrent genomic aberrations in a variety of cancers,
including lymphomas/leukemias.20e22 High frequency of
del6q21 suggests the presence of tumor suppressor gene(s) in
this locus and loss of function that may contribute to the
neoplastic transformation of NK cells and the pathogenesis of
NKCLs. With the application of the high-resolution aCGH
technique, the candidate tumor suppressor genes in del6q21
havebeen identiﬁed.16 Indeed, reconstitution andknock-down
experiments showed that PRDM1 is a tumor suppressor gene
inNKCLs.7,12However, genomicdeletionmayaffectmultiple
genes simultaneously in a genomic locus that may harbor
multiple tumor suppressor genes. In fact, haploinsufﬁciency or
loss of function of multiple tumor suppressor genes may
provide additive or synergistic growth advantage during the
neoplastic transformation of NK cells. Haploinsufﬁciency can
account for the neoplastic transformation through decreased
expression23; however, in most instances, both copies of
a tumor suppressor gene are inactivated with loss of function.54Inactivation of the remaining alleles can occur through
a genetic or epigenetic mechanism,24 and promoter or CpG
island hypermethylation is one of the mechanisms for
silencing tumor suppressor genes.25 SHP1, p73, and PRDM1
have been reported to be silenced through promoter methyl-
ation in NKCLs.16,26,27 In this study, we observed a combi-
nation of deletion and CpG island hypermethylation to be
responsible for the silencing of HACE1 in NKCLs. HACE1
mutations in NKCL cases may be uncommon or not present
according to our analysis. Intronic sequences detected with
RNA-seq may be an artifact of the genomic DNA contami-
nation because no mutation was observed in the intron/exon
junctions by Sanger sequencing, consistent with a previous
report that showed no mutation in the exons and intron/exon
junctions in Wilms tumor cases.3 Ectopic expression of
HACE1 was much less efﬁcient compared with vector-alone
transduction. This phenomenon was frequently observed
during the ectopic expression of the tumor suppressor genes
with the use of unregulated systems, possibly because of early
elimination of transduced cells by the cytotoxic action of these
genes before the experimental endpoints can be tested. This
phenomenon was also observed during the ectopic expression
PRDM1 (BLIMP1), another tumor suppressor gene in the
deleted 6q21 locus, in B- and NK-cell lines, respectively.28,29
In conclusion, we provided strong evidence that HACE1
may be a tumor suppressor gene in NK cell malignancies
by using genetic, epigenetic, and functional approaches.
Further studies are needed to elucidate the putative targets
and the functional role of HACE1 in primary NK cells and
NK cell malignancies.Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2012.09.012.References
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